Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2021-09-23 Regulatory Filings
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-09-23 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that BioVaxys Technology Corp. has engaged a public relations and market communications firm, 6 Degrees, to handle its strategic communications and media relations. It includes background information about the company, statements from the CEO, and forward-looking statements typical of corporate announcements. There are no financial statements, no detailed financial performance data, no regulatory filings, no voting results, no management or board changes, no earnings data, and no mention of any report being attached or published. The content is primarily a corporate announcement about a business engagement related to communications and public relations. This type of document fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Management Reports.
2021-09-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a milestone in the manufacturing process development of a cancer vaccine by BioVaxys Technology Corp. It discusses progress in bioproduction, manufacturing process validation, and upcoming clinical trials. There are no financial statements, regulatory filings, or detailed financial data presented. The content is primarily an operational update and forward-looking statements about the company's development progress. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention the release or availability of a formal report. The document is best classified as a general regulatory announcement or company update that does not fit other specific categories, thus falling under Regulatory Filings (RNS).
2021-09-17 English
News release - English.pdf
Regulatory Filings
2021-09-14 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the results of a scientific study related to the durability of the DTH immune response to SARS-CoV-2, presented at a scientific congress. It includes detailed scientific findings, references to published studies, and forward-looking statements about the company's vaccine development. There are no financial statements, regulatory filings, or formal report structures such as annual or quarterly reports. The document is not a transcript, audit report, or management report. It is a corporate announcement of scientific study results and ongoing research progress, typical of a Regulatory Filing (RNS) as it does not fit other specific categories like Annual Report, Earnings Release, or Investor Presentation. The length is over 10,000 characters, so it is not a brief announcement or report publication notice. Therefore, the best classification is Regulatory Filings (RNS).
2021-09-07 English
News release - English.pdf
Regulatory Filings
2021-08-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.